Ampio Pharmaceuticals, Inc. Message Board
-
Shorts are really hammering AMPE this AM....
..they are trying to hold it down. Short interest is at an all time of 3,600,000 shares. Unfortunately the small float & daily trading volume allows the shorts to manipulate this stock.
Sentiment: Buy
-
It's so easy for the shorts to keep the price down, given that volume is so low. Why is there so little buying?
Sentiment: Buy
- 1 Reply to sirmichael222
-
Maybe I am just a wide-eyed optimist, but I view it as a shortage of sellers. It makes me smile to see the order desk with low prices on the buy side and no sellers willing to dive to those levels... thus... no deals and low volume. With a little news, the smile will turn to a laugh as the shorts try cover. I just hope the sellers stay the course and don't fall for selling at $5 or $6, or even $8... make them squirm.
-
Are the shorts keeping those RKTE message "active" to scare away investors?
Sentiment: Strong Buy
-
You are EXACTLY CORRECT!
Management STILL has not figured out what you have. Small hedge funds that prey on low volume, invisible companies like Ampio because they are easy to manipulate. The have no following because they have no known investment bankers or known analysts. Ampio is an excellent target for the short players because Ampio management is completely blind and ignorant to how the stock market works. Ampio is exceptionally vulnerable to the shorts.
Shares should get a good spike soon when the Zertane deal is announced but they would wind up much higher if they started for $10 or $20 rather than from $4.
If management was as good with IR as they are are with developing their pipeline, Ampio would be at least a $20 dollar stock today and trading volume would average 10 million shares a day.Sentiment: Strong Buy
- 1 Reply to tradersoracle
-
Management, particularly Macaluso & Bar-Or, own a ton of stock & obviously want to see the share price higher. I'm not sure how much more they can do in that regard other than going on a road show. But they don't have any approved drugs yet, and only Optina has started a Phase 3 trial. I'm not sure how this is a $10 or $20 stock yet without some positive news from Phase 3 trials. That being said, all of their 3 primary drug candidates address huge potential markets, and we'll have indications of efficacy from the trials on all 3 drugs before the end of the year. We don't need FDA approvals for the stock to soar, all we need are positive initial indications from the trials. Good Phase 3 data for just one of the drugs - Ampion, Optina, Zertane - will result in a double or triple. If 2 of the drugs succeed, then the sky is the limit.
-